Efficacy and Safety of Gefitinib Combined with Allogeneic CD8<sup>+</sup> NKT Cell Immunotherapy in Advanced <i>EGFR</i>-Mutated Non-Small Cell Lung Cancer

DONG Xiao-rong

doi:10.12019/j.issn.1671-5144.202502014

DONG Xiao-rong. Efficacy and Safety of Gefitinib Combined with Allogeneic CD8+ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 25-26. DOI: 10.12019/j.issn.1671-5144.202502014

Citation:

DONG Xiao-rong. Efficacy and Safety of Gefitinib Combined with Allogeneic CD8+ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 25-26. DOI: 10.12019/j.issn.1671-5144.202502014

Citation:

DONG Xiao-rong. Efficacy and Safety of Gefitinib Combined with Allogeneic CD8+ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2025, 25(1): 25-26. DOI: 10.12019/j.issn.1671-5144.202502014

Efficacy and Safety of Gefitinib Combined with Allogeneic CD8⁺ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer

DONG Xiao-rong

Graphical Abstract

Graphical Abstract

Abstract

FullText(HTML)

References (1)

Efficacy and Safety of Gefitinib Combined with Allogeneic CD8+ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Graphical Abstract

Catalog

Export File

Citation

Format

Content

Efficacy and Safety of Gefitinib Combined with Allogeneic CD8⁺ NKT Cell Immunotherapy in Advanced EGFR-Mutated Non-Small Cell Lung Cancer